



#14  
3-5-03  
DoShenne  
PATENT  
4499-0105P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Pnina FISHMAN Conf.: 4072  
Appl. No.: 09/700,751 Group: 1623  
Filed: January 4, 2001 Examiner: Young  
For: PHARMACEUTICAL COMPOSITIONS COMPRISING  
AN ADENOSINE RECEPTOR AGONIST OR  
ANTAGONIST

RECEIVED  
MAR 04 2003  
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, DC 20231

February 27, 2003

Sir:

In response to the Restriction Requirement mailed January 28, 2003, the following remarks are respectfully submitted in connection with the above-identified application.

REMARKS

Response to Restriction Requirement

Restriction to one of the inventions of Groups I-XVI has been required by the Examiner under 35 U.S.C. 121. The requirement for restriction is respectfully traversed. Reconsideration and withdrawal thereof are requested.

In order to be fully responsive to the Office Action, Applicant elects the invention of Group XI, claims 10-12, 15-18, 20-21, 27 and 41-56, drawn to methods to treat abnormal cell growth such as cancer using an adenosine A3 receptor agonist (A3Rag). However, Applicant respectfully submits that the


invention of Group XIII, claims 41-49, drawn to methods to treat abnormal cell growth using an adenosine A3 receptor agonist (A3RAg) in combination with an adenosine A2 receptor agonist (A2RAg), should also be included together with the invention of Group XI.

Favorable action on the merits is respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
\_\_\_\_\_  
Marc S. Weiner, #32,181  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

MSW/sh  
4499-0105P



1623

PATENT  
4499-0105P

IN THE U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 4 2003

TECH CENTER 1600/29

Applicant: Pnina FISHMAN Conf.: 4072  
Appl. No.: 09/700,751 Group: 1623  
Filed: January 4, 2001 Examiner: Young  
For: PHARMACEUTICAL COMPOSITIONS COMPRISING AN  
ADENOSINE RECEPTOR AGONIST OR ANTAGONIST

SMALL ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents  
Washington, DC 20231

FEB 27 2003

Sir:


Transmitted herewith is a Reply to Restriction/Election Requirement in the above-identified application.

- ☒ Applicant claims small entity status under 37 C.F.R. § 1.27.
- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. A triplicate copy of this sheet is attached.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Marc S. Weiner, #32,181  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

MSW/sh  
4499-0105P